An overview of Panretin and why it is authorised in the EU
Panretin is a medicine used to treat the skin lesions seen in AIDS patients with Kaposi’s sarcoma (a type of skin cancer). Panretin is used when:
- the skin is not broken and the lesions are not swollen,
- the lesions have not responded to HIV treatment,
- other treatments (radiotherapy or chemotherapy) are not suitable, and
- treatment for visceral (internal) Kaposi’s sarcoma is not needed.
Panretin : EPAR - Medicine overview (PDF/83.14 KB)
First published: 29/05/2007
Last updated: 02/07/2018
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
|Date of issue of marketing authorisation valid throughout the European Union||
24/01/2019 Panretin - EMEA/H/C/000279 - IAIN/0045
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Panretin gel is indicated for the topical treatment of cutaneous lesions in patients with acquired-immune-deficiency-syndrome (AIDS)-related Kaposi's sarcoma (KS) when:
- lesions are not ulcerated or lymphoedematous, and;
- treatment of visceral KS is not required, and;
- lesions are not responding to systemic antiretroviral therapy, and;
- radiotherapy or chemotherapy are not appropriate.